Shares of CeriBell (NASDAQ:CBLL - Get Free Report) reached a new 52-week low on Monday . The stock traded as low as $22.81 and last traded at $22.91, with a volume of 47261 shares traded. The stock had previously closed at $24.29.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the company. Canaccord Genuity Group increased their price objective on CeriBell from $31.00 to $33.00 and gave the company a "buy" rating in a research report on Monday, December 9th. TD Cowen raised their price target on CeriBell from $31.00 to $36.00 and gave the company a "buy" rating in a report on Monday, December 9th. Bank of America initiated coverage on CeriBell in a report on Tuesday, November 5th. They set a "buy" rating and a $32.00 price objective for the company. William Blair assumed coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued an "outperform" rating on the stock. Finally, JPMorgan Chase & Co. started coverage on shares of CeriBell in a research note on Tuesday, November 5th. They set an "overweight" rating and a $32.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $32.60.
Read Our Latest Report on CBLL
CeriBell Stock Down 7.2 %
The firm's 50 day moving average price is $27.45.
CeriBell (NASDAQ:CBLL - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The business had revenue of $17.20 million for the quarter, compared to the consensus estimate of $17.06 million. On average, equities analysts predict that CeriBell will post -2.46 EPS for the current year.
About CeriBell
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Further Reading
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
